<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Induction of <z:mp ids='MP_0001799'>viral</z:mp> lytic cycle, which induces <z:hpo ids='HP_0011420'>death</z:hpo> of host cells, may constitute a useful adjunct to current therapeutic regimens for Epstein-Barr virus (EBV)-driven <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Human telomerase reverse transcriptase (hTERT), essential for the oncogenic process, may modulate the switch from latent to lytic <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The possible therapeutic role of hTERT inhibition combined with <z:chebi fb="1" ids="36044">antiviral drugs</z:chebi> was investigated.EXPERIMENTAL DESIGN: EBV-negative BL41 and convertant EBV-positive BL41/B95.8 Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines and lymphoblastoid cell lines (LCL) were infected with retroviral vector encoding short hairpin <z:chebi fb="40" ids="33697">RNA</z:chebi> (shRNA) anti-hTERT and cultured with or without the <z:chebi fb="0" ids="50266">prodrug</z:chebi> <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The effects on EBV lytic replication, cell proliferation, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were characterized.RESULTS: hTERT silencing by shRNA induced the expression of BZLF1, EA-D, and gp350 EBV lytic proteins and triggered a complete lytic cycle </plain></SENT>
<SENT sid="4" pm="."><plain>This effect was associated with downregulation of BATF, a negative regulator of BZLF1 transcription </plain></SENT>
<SENT sid="5" pm="."><plain>hTERT silencing also resulted in antiproliferative and proapoptotic effects </plain></SENT>
<SENT sid="6" pm="."><plain>In particular, hTERT inhibition induced an accumulation of cells in the S-phase, an effect likely due to the dephosphorylation of 4E-BP1, an AKT1-dependent substrate, which results in a decreased availability of proteins needed for cell-cycle progression </plain></SENT>
<SENT sid="7" pm="."><plain>Besides inducing cell <z:hpo ids='HP_0011420'>death</z:hpo> through activation of complete EBV lytic replication, hTERT inhibition triggered AKT1/FOXO3/<z:chebi fb="0" ids="50397">NOXA</z:chebi>-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in EBV-positive and -negative Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> enhanced the apoptotic effect induced by hTERT inhibition in EBV-positive Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and LCLs.CONCLUSIONS: These results suggest that combination of <z:chebi fb="1" ids="36044">antiviral drugs</z:chebi> with strategies able to inhibit hTERT expression may result in therapeutically relevant effects in patients with <z:e sem="disease" ids="C1333432" disease_type="Neoplastic Process" abbrv="">EBV-related malignancies</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Clin <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Res; 1-12. Â©2013 AACR </plain></SENT>
</text></document>